Buy, hold, sell: Medibank Private, Ansell, South32 shares

Let's take a look at some new ratings and opinions from the experts.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) shares are 0.7% lower at 8,943.5 points on Tuesday.

Let's take a look at some new ratings and opinions from the experts.

A man in his late 60s, retirement age, emerges from the Australian surf carrying a surfboard under his arm and wearing a wetsuit.

Image source: Getty Images

Medibank Private Ltd (ASX: MPL)

The Medibank Private share price is $4.61, down 1.2% today and down 8% over 12 months. 

Ord Minnett has a buy rating on this ASX 200 financial share.  

In a new note, the broker said: 

FY26 revenue and earnings from Medibank (MPL) were in-line with expectations, as was the outlook. However, the lack of policyholder growth in the second-half (2H26) was slightly disappointing.

The net number of policyholders grew by 1.1% in the year, with Medibank policyholders up 0.6% and ahm up 2.4%, while non-resident policy units fell 2.3%. In the second-half (2H26), policyholder growth slowed to 0.2%, with the slowdown blamed on cost-of-living pressures, increased switching by customers, and rising competition in the June quarter as some competitors adopted aggressive growth tactics.

Importantly, claims inflation appears relatively benign. Claims growth per policy unit was up 40 bp to 2.6%, at the low end of guidance for 2.6–2.9%. We are comfortable that the 5.1% premium increase achieved by MPL recently can cover claims inflation for FY27. ‍

We keep the Buy recommendation viewing MPL as a relatively defensive option for the next 12 months, with circa 5-10% annual EPS growth on our forecasts.

Ansell Ltd (ASX: ANN)

The Ansell share price is $41.74, down 0.2% today and up 22% over 12 months. 

Mark Elzayed from Vestra Capital has a hold rating on this ASX 200 healthcare share

Elzayed said (courtesy The Bull): 

Ansell makes personal protection equipment for health care and industrial workplaces. It posted global sales of $US2.14 billion in full year year 2026, up 5 per cent on an organic constant currency basis.

Adjusted earnings per share of $US1.486 were up 18.5 per cent, while operating cash flow more than doubled to $US270.1 million.

Ansell remains a defensive compounder with strong cash generation and improving margins, making it a reliable hold for investors seeking income and stability rather than aggressive earnings growth.

South32 Ltd (ASX: S32)

The South32 share price is $5.13, down 0.2% today and up 94% over 12 months.

Blake Halligan from Gray Perry Wealth Advisers has a sell rating on this ASX 200 mining share

Halligan said: 

Stronger commodity prices amid announcing the sale of its aluminium value chain assets to Alcoa for up to $US5.6 billion contributed to an increasing share price.

Revenue rose 1 per cent in fiscal year 2026 when compared to the prior corresponding period. Underlying EBITDA grew 28 per cent.

The stock has risen from $2.64 on September 5, 2025 to trade at $5.20 on September 3, 2026.

Given the big share price increase, commodity price volatility, global uncertainty and execution risk on major projects, investors may want to consider cashing in some gains at this stage of the cycle.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man sitting in a plane looking through a window and working on a laptop.
Broker Notes

Buy, hold, sell: Dicker Data, Polynovo, Flight Centre shares

Here's what the experts think.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher

After slumping to a 9-year low on 3 June, healthcare shares have rallied by an extraordinary 42%.

Read more »

A baby's eyes open wide in surprise as it sucks on a milk bottle.
Broker Notes

How high could Bubs Australia shares go, according to Bell Potter?

A key approval is expected to boost the Bubs share price.

Read more »

a woman in a business suit looks wide eyed and interested as she holds a tin can with string to hear ear listening to some news.
Broker Notes

UBS names its 10 top ASX picks for the next 3-6 months

Here are the 10 ASX shares UBS thinks could outperform.

Read more »

Happy teen friends jumping in front of a wall.
Broker Notes

Guess which ASX stock could rise 85%

Bell Potter sees significant upside from this stock.

Read more »

Buy the dip written on a yellow sign.
Broker Notes

Down 43%! 4 reasons to buy the BIG dip in Pro Medicus shares today

A leading expert believes Pro Medicus shares are well-place to rebound.

Read more »

Sell written several times on board.
Broker Notes

Sell alert! Why this expert is calling time on Flight Centre and CBA shares

A leading analyst expects Flight Centre and CBA shares will continue to struggle in FY 2027.

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

4 high conviction ASX stock picks from Canaccord Genuity

The valuations of these stocks are looking attractive, the broker says.

Read more »